ResearchMoz

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

GBI Research
Published Date » 2013-04-15
No. Of Pages » N/A
     
  ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment  
   
 GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.  
   
 The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary...
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to 2018 – Executive Summary

3 ADHD Therapeutics Market to 2018 – Introduction
3.1 Etiology and Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
3.2.1 Child/Adult Subpopulations
3.2.2 Male/Female
3.3 Diagnosis
3.3.1 DSM-IV Criteria for ADHD
3.3.1.1 DSM-V Revision
3.3.2 ICD-10 Criteria for Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues with Diagnosis
3.3.5 Co-Morbid Disorders
3.4 Treatment and Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers and Barriers for ADHD Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence of ADHD
3.5.1.2 Need for Effective Non-Stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level of Co-Morbidity
3.6 Report Guidance

4 ADHD Therapeutics: Market Characterization by Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost of Therapy – Average of All Major Markets
4.2 The US
4.2.1 Market Size – The US
4.2.2 Market Forecast - The US
4.2.3 Annual Cost of Therapy – The US
4.3 Top 5 Countries of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
4.3.12 Annual Cost of Therapy – Spain
4.3.13 Market Size – The UK
4.3.14 Market Forecast – The UK
4.3.15 Average Annual Cost of Therapy – The UK
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost of Therapy – Japan

5 ADHD Therapeutics Market to 2018 – Competitive Landscape
5.1 Overview of Major Marketed Products in the ADHD market
5.1.1 Adderall XR (mixed amphetamine salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate transdermal patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin XR (dexmethylphenidate hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
5.1.8.3 Safety
5.1.9 Generic products

6 ADHDTherapeutics Market to 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
6.3 Trends in the ADHD Therapeutic Pipeline

7 ADHD Therapeutics Market to 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals by Deal Type
7.1.2 Deals by Year
7.1.3 Deals by Geography
7.1.4 Deals by Value
7.2 M&A Landscape
7.2.1 M&A Deals by Deal Type
7.2.2 M&A Deals by Year
7.2.3 M&A Deals by Geography
7.2.4 M&A Deals by Deal Value
7.2.5 Sanofi-Aventis Merger, 2004
7.3 R&D Licensing Agreements
7.3.1 Deals by Year
7.3.2 Deals by Geography
7.3.3 Deals by Deals Value
7.3.4 Targacept and AstraZeneca Agreement, 2009
7.4 Co-Development Agreements
7.4.1 Deals by Year
7.4.2 Deals by Geography
7.4.3 Deals by Deal Value
7.4.4 Shire and New River Co-Development Deal, 2005

8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size by Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer

List of Tables

Table 1: DSM-IV criteria for attention deficit hyperactivity disorder
Table 2: CD-10 criteria for hyperkinetic disorders
Table 3: ADHD Therapeutics, Marketed Products Overview, 2012
Table 4: ADHD Therapeutics, Pre-Clinical Pipeline, 2012
Table 5: ADHD Therapeutics, Phase I Pipeline, 2012
Table 6: ADHD Therapeutics, Phase II Pipeline, 2012
Table 7: ADHD Therapeutics, Phase III 2012
Table 8: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Table 9: M&A Deals by Deal Value

List of Figures

Figure 1: ADHD All Major Markets Market Size ($m) 2006-2011
Figure 2: ADHD All Major Markets Market Forecast ($m) 2012-2018
Figure 3: ADHD Annual Cost of Therapy All Markets ($) 2006-2018
Figure 4: ADHD Market Size US ($m) 2006-2011
Figure 5: ADHD Market Forecast US ($m) 2012-2018
Figure 6: ADHD Annual Cost of Therapy The US ($) 2006-2018
Figure 7: ADHD Market Size France ($m) 2006-2011
Figure 8: ADHD Market Forecast France ($m) 2012-2018
Figure 9: ADHD Annual Cost of Therapy France ($) 2006-2018
Figure 10: ADHD Market Size Germany ($m) 2006-2011
Figure 11: ADHD Market Forecast Germany ($m) 2012-2018
Figure 12: ADHD Annual Cost of Therapy Germany ($) 2006-2018
Figure 13: ADHD Market Size Italy ($m) 2006-2011
Figure 14: ADHD Market Forecast Italy ($m) 2012-2018
Figure 15: ADHD Annual Cost of Therapy Italy ($) 2006-2018
Figure 16: ADHD Market Size Spain ($m) 2006-2011
Figure 17: ADHD Market Forecast Spain ($m) 2012-2018
Figure 18: ADHD Annual Cost of Therapy Spain ($) 2006-2018
Figure 19: ADHD Market Size UK ($m) 2006-2011
Figure 20: ADHD Market Forecast UK ($m) 2012-2018
Figure 21: ADHD Annual Cost of Therapy The UK ($) 2006-2018
Figure 22: ADHD Market Size Japan ($m) 2006-2011
Figure 23: ADHD Market Forecast Japan ($m) 2012-2018
Figure 24: ADHD Therapeutics – Pipeline by Phase of Development, 2012
Figure 25: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Figure 26: ADHD Therapeutics – Pipeline by Program Type, 2012
Figure 27: ADHD Therapeutics – Inactive/Discontinued Pipeline Molecules by Target, 2012
Figure 28: Total Deals by Deal Type
Figure 29: Total Deals by Year
Figure 30: Total Deals by Geography
Figure 31: Total Deals by Deal Value
Figure 32: M&A Deals by Deal Type
Figure 33: M&A Deals by Year
Figure 34: M&A Deals by Geography
Figure 35: R&D Licensing Agreements Deals by Year
Figure 36: R&D Licensing Agreements Deals by Geography
Figure 37: R&D Licensing Agreements Deals by DealsValue
Figure 38: Co-Development Agreements Deals by Year
Figure 39: Co-Development Agreements Deals by Geography
Figure 40: Co-Development Agreements Deals by Deal Value
Figure 41: GBI Research Market Forecasting Model

Upcoming Reports:

Electric Handheld BP Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Electric handheld blood pressure (BP) devices have several advantages over conventional blood pressure measuring devices such as ease of use, quick results, easy to interpret and portability. Because of these advantages, conventional BP devices are greatly being replaced by modern automated BP measuring devices. These portable digital BP devices have enabled patients to monitor their blood pressure at regular interval of time at their home. Digital screens of these devices make reading results easier than reading values on conventional devices. They also do not require stethoscope,...
Influenza Vaccine Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018
By - Transparency Market Research
Influenza Vaccine is also called as flu shot and is used for protection against influenza virus. An influenza vaccine is a combination of three influenza viruses namely, influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain. Over the recent years, the Influenza Vaccine market has witnessed double digit growth rate due to fear of an impending pandemic. The Influenza Vaccine market has grown at a CAGR of approximately 65% between 2008 and 2010 due to the havoc caused by H1N1 virus. However, H1N1 flu vaccine...
Middle East Cyber Security Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Cyber security (or computer security) refers to the security applied to entire web (cyber) world, which includes everything from computers to smartphone and other automated devices with web-connectivity. The prime objective is to ensure the confidentiality of the information shared across the network. It is also applied to data monitoring in public and private computer networks including the internet to ensure information security. The cyber security enables protection from attacks such as unauthorized access, hacking, injection of codes such as virus and Trojans and other vulnerabilities....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...
Defense Workers Start a 10-Day Strike over Pay
Dec 8, 2014  
Members of Unite at the Defense Support Group are going to walk out on Monday protesting at a 1% pay offer. The group keeps repairing and renovating military equipment for the Ministry of Defense.  The Unite national officer, Mr. Mike McCartney, stated that Defense Support Group was cash-rich and asked them to take up negotiations for a fair pay deal again. The Ministry of Defense...
Record US$100 Mn Donated to the University of North Carolina for Pharmacy School
Dec 4, 2014  
The “Innovation Engine” received a US$100 million fund in the effort to create innovation at the UNC Eshelman School of Pharmacy, reported Chapel Hill, The University of North Carolina on Wednesday.  The donation is contributed from a 1972 graduate - Fred Eshelman who is also the founder of the Pharmaceutical Product Development and Furiex Pharmaceuticals. The money is...